LifeTech Capital Raises StemCells PT to $8, Maintains Strong Speculative Buy

LifeTech Capital raised its StemCells (NASDAQ: STEM) (NASDAQ: STEMD) price target from $1.60 to $8 and maintained its Strong Speculative Buy rating in a research report published today.

In the report, LifeTech Capital states, "StemCells Inc. executed a 1:10 reverse split on July 6th and will trade under the symbol STEMD for the next 20 trading days. While the split-adjusted price will be attractive to institutions, we believe there could be an offsetting decrease in trading liquidity."